SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Druker Brian J.)
 

Search: WFRF:(Druker Brian J.) > (2008) > Imatinib pharmacoki...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Larson, Richard A (author)

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

  • Article/chapterEnglish2008

Publisher, publication year, extent ...

  • American Society of Hematology,2008

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/197816
  • https://gup.ub.gu.se/publication/197816URI
  • https://doi.org/10.1182/blood-2007-10-116475DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-170111URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Bengt Simonsson, Institutionen för medicinska vetenskaper, Medicin (Hematologi) ingår i IRIS Study Group
  • Imatinib at 400 mg daily is standard treatment for chronic myeloid leukemia in chronic phase. We here describe the correlation of imatinib trough plasma concentrations (C(mins)) with clinical responses, event-free survival (EFS), and adverse events (AEs). Trough level plasma samples were obtained on day 29 (steady state, n = 351). Plasma concentrations of imatinib and its metabolite CGP74588 were determined by liquid chromatography/mass spectrometry. The overall mean (+/- SD, CV%) steady-state C(min) for imatinib and CGP74588 were 979 ng/mL (+/- 530 ng/mL, 54.1%) and 242 ng/mL (+/- 106 ng/mL, 43.6%), respectively. Cumulative estimated complete cytogenetic response (CCyR) and major molecular response (MMR) rates differed among the quartiles of imatinib trough levels (P = .01 for CCyR, P = .02 for MMR). C(min) of imatinib was significantly higher in patients who achieved CCyR (1009 +/- 544 ng/mL vs 812 +/- 409 ng/mL, P = .01). Patients with high imatinib exposure had better rates of CCyR and MMR and EFS. An exploratory analysis demonstrated that imatinib trough levels were predictive of higher CCyR independently of Sokal risk group. AE rates were similar among the imatinib quartile categories except fluid retention, rash, myalgia, and anemia, which were more common at higher imatinib concentrations. These results suggest that an adequate plasma concentration of imatinib is important for a good clinical response. This study is registered at http://clinicaltrials.gov as NCT00333840.

Subject headings and genre

  • MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin hsv//swe
  • MEDICAL AND HEALTH SCIENCES Clinical Medicine hsv//eng
  • Adolescent
  • Adult
  • Age Distribution
  • Aged
  • Antineoplastic Agents
  • adverse effects
  • blood
  • pharmacokinetics
  • therapeutic use
  • Benzamides
  • Body Surface Area
  • Body Weight
  • Demography
  • Disease-Free Survival
  • Female
  • Humans
  • Leukemia
  • Myeloid
  • Chronic-Phase
  • drug therapy
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Piperazines
  • adverse effects
  • blood
  • pharmacokinetics
  • therapeutic use
  • Prognosis
  • Pyrimidines
  • adverse effects
  • blood
  • pharmacokinetics
  • therapeutic use
  • Treatment Outcome

Added entries (persons, corporate bodies, meetings, titles ...)

  • Druker, Brian J (author)
  • Guilhot, Francois (author)
  • O'Brien, Stephen G (author)
  • Riviere, Gilles J (author)
  • Krahnke, Tillmann (author)
  • Gathmann, Insa (author)
  • Wang, Yanfeng (author)
  • Wadenvik, Hans,1955Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine(Swepub:gu)xwadha (author)
  • Göteborgs universitetInstitutionen för medicin, avdelningen för invärtesmedicin (creator_code:org_t)

Related titles

  • In:Blood: American Society of Hematology111:8, s. 4022-80006-49711528-0020

Internet link

Find in a library

  • Blood (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view